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The microenvironment in mature B-cell malignancies: a target for new treatment
strategies
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Despitemajortherapeuticadvances,most
mature B-cell malignancies remain incur-
able. Compelling evidence suggests that
crosstalk with accessory stromal cells in
specialized tissue microenvironments,
such as the bone marrow and secondary
lymphoidorgans,favorsdiseaseprogres-
sion by promoting malignant B-cell
growth and drug resistance. Therefore,
disrupting the crosstalk between malig-
nant B cells and their milieu is an attrac-
tive novel strategy for treating selected
matureB-cellmalignancies.Herewesum-
marize the current knowledge about the
cellular and molecular interactions be-
tween neoplastic B lymphocytes and ac-
cessory cells that shape a supportive
microenvironment, and the potential
therapeutic targets that are emerging, to-
gether with the new problems they raise.
We discuss clinically relevant aspects
andprovideanoutlookintofuturebiologi-
cally oriented therapeutic strategies. We
anticipate a paradigm shift in the treat-
ment of selected B-cell malignancies,
movingfromtargetingprimarilythemalig-
nant cells toward combining cytotoxic
drugs with agents that interfere with the
microenvironment’s proactive role. Such
approaches hopefully will help eliminat-
ing residual disease, thereby improving
our current therapeutic efforts. (Blood.
2009;114:3367-3375)
Introduction
The microenvironment is the compilation of accessory cells that
within individual organs work as a team through cell-cell contacts
and active molecular crosstalk to provide a functional scaffolding
to parenchymal cells. In solid tumors, a microenvironment instru-
mental to the survival and propagation of malignant cells is built up
by the concurrence of inﬂammatory cells that produce growth
factors, new vessel formation that provides nutrients, and immune
tolerance that avoids immune-mediated elimination. Conceivably,
this conducive microenvironment may be an appropriate soil to
host cancer stem cells (CSCs). Signals from the tumor microenvi-
ronment are a major hurdle to cancer cell eradication, and its
neoangiogenetic component has become an attractive target for
treatment strategies that aim at perturbing the nurturing capacity of
the tumor cell milieu.1
Blood cancers develop in specialized tissue microenviron-
ments, such as bone marrow (BM) and secondary lymphoid
organs. These microenvironments are characterized by different
populations of accessory stromal and T cells that interact with
malignant cells and promote tumor growth and drug resis-
tance.2,3 Malignant blood cells apparently have highly variable
degrees of dependency on signals from the microenvironment.
To make matters more complex, the afﬁnity and dependency on
accessory stromal cells for tumor growth and progression can
change over time, with the evolution of stroma-dependent or
stroma-independent subclones.
The issue of microenvironment-targeted treatment has recently
gained increasing attention in hemato-oncology, and the enthusi-
asm in this ﬁeld is justiﬁed by a number of new drugs that are
targeted toward the microenvironment, such as thalidomide and
lenalidomide, plerixafor, and natalizumab.4 At this point, the main
questions are which blood malignancies may mostly beneﬁt from
microenvironment-targeted approaches, what are the potential
therapeutic targets, and what are the problems they raise.
Microenvironment and blood cancers
Therelationshipsbetweenneoplasticbloodcellsandmicroenviron-
ment appear to follow 3 major patterns whose better deﬁnition may
provide clues for future microenvironment-targeted treatments.
The ﬁrst pattern may be referred to as loss of interconnection
with the microenvironmental network, which occurs when a
genetic abnormality provides transformed cells with a sustained
proliferation advantage that is largely autonomous and independent
of microenvironmental signals. A typical example is Burkitt
lymphoma, where virtually all malignant B cells are determined to
proliferate because of the chromosomal translocation that leads to
perennial c-myc gene activation. Accordingly, in Burkitt lym-
phoma, the microenvironment appears to have a limited role in
planning new treatment strategies.
The second pattern is a dysfunctional environment, where the
neoplasticcellsengageinderegulatedinteractionswiththesupport-
ive stroma that provide the malignant cells with growth- and
drug-resistance signals. Examples are the acute leukemias and
myelodysplastic syndromes, where leukemia stem cells (LSCs)
escape the tightly regulated cell growth- and proliferation-control
within the hematopoietic niches, and instead parasitize in the
supportive hematopoieic microenvironment. Here, the dependency
of the neoplastic cells on the stromal counterparts for growth and
survival is partially retained and may lead to the survival of clones
endowed with a higher afﬁnity for the microenvironment.4,5
Accordingly, in these diseases, targeting the microenvironment is
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which otherwise survive conventional treatments and pave the way
for relapses.
The third pattern, a friendly, regulated coexistence of the
malignant cells and the microenvironment, is apparent in subsets of
B-cell tumors, such as chronic lymphocytic leukemia (CLL),
follicular lymphoma (FL), mucosa-associated lymphoid tissue
(MALT) lymphomas, and multiple myeloma (MM). Here, the
interactions between the malignant cells and the microenvironment
largely resemble the pattern that the normal counterpart B cells
engage in with their respective microenvironments. Consequently,
the proliferative drive for the malignant cells is, at least initially,
largely dependent on external signals from the microenvironment,
such as antigens, cytokines, and cell-cell interactions, and the
neoplastic cells undergo apoptosis unless their survival is rein-
forced by these external stimuli. These interactions are not targeted
by our current “conventional” treatments, which may explain why,
despite major therapeutic advances, some B-cell malignancies still
remain incurable. Based on this concept, these tumors are expected
to be particularly responsive to microenvironment-directed treat-
ment approaches.
Bone marrow and secondary lymphoid
organs have different microenvironments
Blood-forming BM and secondary lymphoid organs have entirely
different microenvironments, each ﬁnely tuned to support different
aspects of lymphocyte maturation and differentiation. The BM
harbors hematopoietic stem cells (HSCs) and hosts the develop-
ment of mature B cells from committed progenitors. The latter
process is primarily concerned with the events that lead to the
production of cells endowed with a functional antigen (Ag)
receptor (B-cell receptor [BCR]). Mature B cells migrate to
secondary lymphoid organs where they are exposed to Ag within
germinal centers (GCs) of secondary lymphoid follicles. The
microenvironment of GC allows maturing B cells to interact with
CD4 T cells for the necessary help on Ag recognition and with
specialized stromal cells, follicular dendritic cells (FDCs), for the
required quality control after afﬁnity maturation.6,7TheAg encoun-
ter triggers the proliferation, maturation, and ﬁnal differentiation
into effector plasma cells (PCs) and memory B cells.8
In the BM, accessory “feeder” cells maintain HSCs within
specialized “niches,” which are close to the marrow vasculature
(vascular niche) or to the endosteum (osteoblast niche).9 The
concept of niches appears to apply to CSCs as well.As an example,
LSCs not only share phenotypic and functional characteristics with
normal HSCs10 but also preferentially localize within HSC niches11
(Figure 1A). The BM development of B cells from early progeni-
tors requires their intimate contact with a heterogeneous population
of adherent cells collectively referred to as “stroma.”12 The
importance of stromal cells for hematopoiesis was initially demon-
strated in long-term BM cultures13 and was used by Whitlock and
Witte to develop a culture system to study the early stages of B-cell
maturation.14
Implications for mature B-cell malignancies
The microenvironment of mature B-cell tumors mirrors the micro-
environment of the tissue where the tumor develops. It shares the
general properties of cancer microenvironment with the presence
of abundant different populations of stromal cells that favor the
survival of malignant cells, various subsets of T cells that may
support the disease progression, overcoming the antitumor effect
exerted by still other speciﬁc T-cell subsets, and endothelial cells
that organize neoangiogenetic microvessels. The clinical relevance
of microenvironment is exempliﬁed by the observation that the
length of survival among patients with FL correlates with the
molecular features of nonmalignant immune cells present in the
tumor at diagnosis,15 and those differences in immune cells,
ﬁbrosis, and angiogenesis in tumor environment inﬂuence the
Figure 1. Cellular interactions. (A) Marrow and (B) lymphatic tissue microenvironments in mature B-cell tumors. (A) MSCs (arrow), also called reticular cells, are scattered
throughout the marrow cavity and constitutively secrete high levels of the chemokine CXCL12 (SDF-1). MSCs colocalize with the vasculature, forming so-called “vascular
niches.” CXCL12 secretion by MSC induces CXCL12 gradients that can attract circulating neoplastic B cells via CXCR4 receptors expressed on CLLs, MM, and other
malignant B cells. Circulating lymphoma cells may become attracted by CXCL12 gradients to home to the marrow where contact with MSCs provides them with growth and
survival signals. Mesenchymal-derived osteoblasts are specialized ﬁbroblasts critical for bone formation and able to secrete CXCL12.Therefore, interaction with osteoblasts is
an alternative, additional niche where lymphoma cells can home. These cellular interactions also confer drug resistance to leukemia/lymphoma cells and may therefore
account for MRD. (B) In secondary lymphoid tissues, CLLcells and other lymphoma cells can interact with a variety of accessory cells, such as MSCs, monocyte-derived NLCs,
which are similar to LAMs, andT cells.The presence of FDCs in lymphoid tissues in CLLis controversial. Formation of proliferation centers is a hallmark of CLLhistopathology.
Interactions between CLL and accessory cells within proliferation centers are critical for providing growth and survival signals to CLL B cells, inducing their proliferation and
resembling interactions between normal, antigen-stimulated B cells and accessory cells (antigen-presenting cells, T cells) during GC reaction. CLL cells outside the
proliferation centers are resting and considered the nonproliferative compartment.
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(DLBCL).16 LSCs have not (yet) been identiﬁed in B-cell tumors,
and it remains unresolved whether these tumors are nurtured by
LSCs that ﬁnd their optimal soil in speciﬁc microenvironments or
whether they are rather uniform mature B-cell clones that become
exposed to microenvironmental growth signals in speciﬁc tissues.
Furthermore, and because of the speciﬁc features of B cells, other
players, such as Ag stimulation and the molecules involved in
lymphocyte trafﬁc, are more speciﬁcally operating in the microen-
vironments of B-cell tumors.Angiogenesis also is a major player in
the microenvironment of B-cell lymphomas, although its role in
B-cell tumors is currently less well deﬁned compared with solid
tumors,17 where antiangiogenic strategies have become an impor-
tant therapeutic modality in metastatic disease. B-cell lymphoma
growth is enhanced by at least 2 angiogenic mechanisms: autocrine
stimulation of tumor cells via expression of vascular endothelial
growth factor and vascular endothelial growth factor receptors by
lymphoma cells, such as CLL,18 DLBCL, and mantle cell lym-
phoma cells, as well as paracrine effects on local neovasculariza-
tion and recruitment of circulating endothelial progenitors. The
efﬁcacy of antiangiogenic treatment approaches in mature B-cell
malignancies is currently explored in clinical trials.17
Antigen stimulation in mature B-cell
malignancies
The very raison d’e ˆtre of mature B cells is their Ag receptor. It
follows that in speciﬁc B-cell malignancies the concept of microen-
vironment as a regulator of malignant B-cell growth is tightly
linked to the possible role of Ag stimulation.19 Chronic BCR
stimulation by latent microbial or auto-Ag can trigger the develop-
ment and expansion of malignant B cells. Classic examples are the
development of gastric MALTlymphomas in the context of chronic
Helicobacter pylori infection20,21 and of lymphomas within sali-
vary glands in Sjogren syndrome or the thyroid in Hashimoto
thyroiditis. The list of B-cell tumors where microorganisms
provide antigenic lymphomagenic stimuli is growing and includes
hepatitis C virus in splenic marginal zone lymphoma,22 Borrelia in
cutaneous marginal zone lymphoma,22,23 Chlamydia psittaci in
ocular adnexal marginal zone lymphoma,22,24 and possibly also
Campylobacter jejuni in immunoproliferations of the small
intestine.22
The existing data also indicate that molecular structures
normally involved in eliminating cellular debris, scavenging
apoptotic cells, and providing a ﬁrst line of defense against
pathogenic bacteria may trigger and/or facilitate the onset and
evolution also of CLL.25-27
Most patients with FLhave somatically mutated immunoglobu-
lin variable (IGVH) genes with intraclonal variation, consistent
with their origin from GC. Surprisingly, these IGVH genes almost
always carry introduced motifs available for N-glycosylation that
are uncommon in normal B cells, very rare in CLL, undetectable in
MM, although evident in a proportion of DLBCLs, suggesting a
site-speciﬁc role.28 Most novel glycosylation sites are located in the
complementary-determiningregionssites,possiblyprecludingcon-
ventionalAg binding and contain oligomannose glycans, which are
expressed by tumor cell surface IgM. As binding studies indicate
that the oligomannose glycans occupying the variable regions are
accessible to mannose-binding lectin, the possibility is raised, that
within malignant GC, the Ag stimulation operating in other B-cell
tumors might be mimicked by the interaction of the tumor cell BCR
with mannose-binding molecules of innate immunity.29 A possible
BCR reactivity has also been shown in DLBCLwhere it appears to
carry a prognostic signiﬁcance.30 The majority of examined
primary DLBCLs were found to exhibit both tonic- and ligand-
induced BCR signaling, which could be identiﬁed by transcrip-
tional proﬁles and was abrogated by an inhibitor of spleen tyrosine
kinase (Syk).30
In MM both the IgVH mutational status31 and the actual
paraprotein reactivity identiﬁed in some instances32 document that
Ag stimulation is somehow instrumental in triggering the onset of
the diseases. Whether a persistent Ag stimulation may fuel the
disease by providing persistent waves of Ag-speciﬁc plasmablasts
is a matter of speculation.
The issue becomes how we might use all this information for
designing therapeutic strategies. One obvious possibility is to
identify the stimulatingAg, especially if it is of microbial origin
and interferes with its activity, an approach successfully applied
to H pylori– and C psittaci–related lymphomas. Another option
is to learn how to manipulate the B-cell response triggered by
the BCR stimulation. The possibility of targeting the signal
transduction pathways activated in malignant B cells by micro-
environmental interactions exists considering the impressively
rapid progress in the ﬁeld of (kinase-) signaling inhibitors.
Unfortunately, signal transduction pathways are generally redun-
dant: if one is switched off, others remain intact and can bypass
the inhibitors. Master signaling pathways tend to be used in
various cell types, and targeting these pathways might lead to
unwanted severe side effects.
Malignant B-cell trafﬁcking, chemokine
receptors, and adhesion molecules
Evidence is growing that malignant B cells exploit the physiologic
mechanisms of tissue-speciﬁc lymphocyte migration and homing
to access supportive microenvironmental niches.
The exquisite homing to and within the BM of malignant
B cells, such as MM33 and CLL cells,34 is mediated by the
chemokine receptor CXCR4.35 This allows malignant B cells to
interact with CXCL12-expressing mesenchymal stromal cells
(MSCs),5 which in turn provide ligands for adhesion molecules,
such as VLA-4 (CD49d) or CD44.36 VLA-4–mediated adhesion to
ﬁbronectin confers a survival advantage and inhibits drug-induced
apoptosis (cell adhesion–mediated drug resistance) in MM37 and
other hematopoietic malignancies. Activation of CXCR4 and
CXCR5 induces signals related to cell growth, such as p44/42
MAP kinase-(ERK1/2) and STAT3,38 and prolongs the survival of
CLL cells,39,40 indicating that chemokine receptor activation not
only attracts neoplastic B cells but also directly regulates their fate.
MM PCs express on the membrane adhesion molecules, such as
H-CAM(CD44),ICAM-I(CD54),N-CAM(CD56),LFA-3(CD58),
the proteoglycan syndecan, a receptor for hyaluronan-mediated
motility, and frequently also CD11/CD18.36,41,42 The interaction of
MM surface adhesion structures with their homologous ligands
within the BM microenvironment allows malignant PCs to be
entrapped within the BM stromal cell web. There, they encounter
locally produced cytokines enriched on the extracellular matrix
protein layers.
FL43,44 and mantle cell lymphoma cells45 also express surface
chemokine receptors, particularly CXCR4 and CXCR5,44,45 and
adhesion molecules that allow for the homing and retention within
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peptides that compete with CD49d ligands inhibit malignant B-cell
adhesion46,47 to stromal cells and enhance the activity of cytotoxic
drugs. Accordingly, drugs targeting CD49d, other adhesion mol-
ecules, or their stromal ligands, should also be evaluated in selected
B-cell malignancies.
Lessons from the analysis of different B-cell
malignancies
Individual B-cell malignancies have unique microenvironment
properties whose detailed analysis raises a number of issues
important for planning new therapeutic strategies.
Microenvironment in CLL
CLL cells relentlessly accumulate in vivo but rapidly undergo
spontaneous apoptosis in vitro, implying that their apoptosis
resistance, rather than being an intrinsic feature of leukemic cell,
depends on external signals.2,3,19 This is not surprising considering
that also the maturation stages of normal B cells are highly
dependent on microenvironment signals.48 Starting from the origi-
nal studies, which used unselected BM stromal cells,39,49 growing
evidence suggests that different types of stromal cells, such as
monocyte-derived nurselike cells (NLCs),39 MSCs,39,49 or even
FDCs50 protect CLLcells in coculture and are an integral part of the
CLLmicroenvironment.
NLCs owe their name to the similarities with thymic nurse cells
that nurture developing thymocytes.39 In vitro, NLCs differentiate
from blood monocytes cocultured with CLL cells.39 In vivo, NLCs
can be found in the spleen and lymphoid tissues of CLL patients.51
They attract CLL cells by secreting CXCL1239 and CXCL1352 and
protect CLL cells from spontaneous or drug-induced apoptosis
through CXCL12,39,40 B cell–activating factor of the tumor necro-
sis factor family (BAFF), a proliferation-inducing ligand,40 CD31,
and plexin-B153 (Figure 2).
MSCs are known to profoundly inﬂuence the development and
progression of various cancers.56 In CLL38 and other B-cell
malignancies, such as MM57 as well as in a murine mature B-cell
lymphoma model,54 MSC-derived survival and drug resistance
signals are largely adhesion-dependent. Coculture with MSC
results in the rapid, spontaneous migration of a fraction of CLL
cells beneath and underneath the MSCs (pseudoemperipolesis),
inducing a cobblestone-like appearance.34 This migration depends
on CXCR4 and VLA-4 expression by leukemia cells34 and
exempliﬁes the migratory potential and the need for adhesive
interactions between CLL cells and the microenvironment. Adhe-
sion molecules, particularlyVLA-4 integrins, along with CD44 and
gelatinase B/matrix metalloproteinase-9,58 cooperate with chemo-
kine receptors in CLLcell adhesion to stromal cells.46 Interestingly,
VLA-4 expression on CLLcells has prognostic impact,59 indicating
the relevance of these interactions in vivo.
Figure 2. Molecular crosstalk between malignant B cells, exempliﬁed for CLL B cells, and the microenvironment. This ﬁgure displays the molecules involved in
crosstalk between CLL cells and accessory cells in the marrow and/or lymphoid tissue microenvironments. Contact between CLL cells (and various other mature B-cell
lymphomas, as detailed in the text) and NLCs/LAMs or MSCs is established and maintained by chemokine receptors and adhesion molecules. NLCs express the chemokines
CXCL12 and CXCL13, whereas MSCs predominantly express CXCL12. NLCs and MSCs attract CLL cells via the G protein–coupled chemokine receptors CXCR4 and
CXCR5, which are expressed at high levels on CLL cells. Integrins, particularly VLA-4 integrins (CD49d), expressed on the surface of CLL cells cooperate with chemokine
receptors in establishing cell-cell adhesion through respective ligands on the stromal cells (VCAM-1 and ﬁbronectin/FN). NLCs also express the TNF family members BAFF
and a proliferation-inducing ligand, providing survival signals to CLL cells via corresponding receptors (BCMA, TACI, BAFF-R). CD38 expression allows CLL cells to interact
with CD31, the ligand for CD38, expressed by stromal and NLCs. Ligation of CD38 activates ZAP-70 and downstream survival pathways. Self and/or environmental antigens
(Ag) are considered a key factor in stimulation and expansion of the CLLclone.The nature and source ofAg and its mode of presentation in CLLs are unknown and currently the
focus of intensive research. Stimulation of the BCR complex (BCR and CD79a,b) induces downstream signaling by recruitment and activation of Syk and ZAP-70. BCR
stimulation and coculture with NLCs also induce CLL cells to secrete high levels of the chemokines CCL3 and CCL4, which are potent T cell–attracting chemokines. Through
this mechanism, CLLcells can actively recruit T cells for cognate T-cell interactions with CLLcells. CD40L T cells are preferentially found in CLLproliferation centers and can
interact with CLL cells via CD40. Cytokines secreted by T cells or CLL cells, such as IL-4, or TNF- are considered important regulators of CLL cell survival. Hedgehog (Hh)
proteins, such as the indian (Ihh) and sonic (Shh) hedgehog proteins, are stromal cell–derived factors that can regulate survival of CLLand other mature B-cell malignancies.54
ROR1, an oncofetal antigen with CLL-restricted expression, may function as receptor for Wnt5a,55 expressed by stromal cells. Collectively, this crosstalk between CLLcells and
accessory cells results in activation of survival and drug resistance pathways, such as those provided by Bcl-2 and Mcl-1.
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the presence of focal aggregates of proliferating cells that cluster in
pseudofollicular structures, named proliferation centers or pseudo-
follicles (Figure 1B).3 The architecture and cellular composition of
proliferation centers include different Ag-presenting cells and
numerous CD4 T cells25,60 (Figure 1B), suggesting that some of
the mechanisms required for the expansion of Ag-speciﬁc normal
B cells within GC may also be operating in CLL. Still the processes
accounting for the development and maintenance of pseudofol-
licles are unknown. CXCL13, a chemokine critical in establishing
the architecture of normal follicles, probably plays a role. CXCL13
is constitutively secreted by FDCs and NLCs and is a potent
chemoattractant for CLLcells.52 Recent data suggest that CLLcells
are not mere passive seeds that need to home into the appropriate
soil but rather active players that create a supportive microenviron-
ment. CLL cells, after BCR stimulation or exposure to NLCs,
secrete chemokines, such as CCL22,60 CCL3, and CCL4,61,62
which can attract other supportive cells, such as T cells. This
indicates the possibility that the CLL microenvironment is created
and maintained through a dynamic, interactive coevolution be-
tween leukemic and normal bystander cells.
The role of T cells in CLL can be seen from different,
nonmutually exclusive angles. One possibility is that T-cell subsets
may help favor disease progression, overcoming the antitumor
effect exerted by other speciﬁc T-cell subsets. In this context, the
role and functional signiﬁcance of regulatory T cells (Treg) and 
T cells in the CLL microenvironment are imperfectly deﬁned.63
Another possibility is that T-cell abnormalities may provide the
biologic basis of the signiﬁcant immune deﬁciency that is typical of
CLL. The recently identiﬁed impaired formation of immunologic
synapse might represent an important element of immune dysfunc-
tion,64 especially because this abnormality can also be induced in
healthy allogeneic T cells after contact with CLL cells. Further, the
possibility of reversing this defect with the immunomodulatory
drug lenalidomide is of therapeutic interest.64,65
The overall number of circulating T cells, oligoclonal in both
the CD4 and the CD8 compartment,66 is increased in untreated
CLL patients. It is still unresolved whether these expanded T cells
display immune reactivity to the malignant clone or rather target
microbial antigens that are more prevalent in CLLpatients because
of their chronic immunosuppression. Functionally, they can stimu-
late CLL cell growth and survival by secreting cytokines, such as
interleukin-4 (IL-4) or tumor necrosis factor- (TNF-)19 (Figure
2). Within proliferation centers, a signiﬁcant proportion of T cells
display CD40L (CD154),25 a member of the TNF superfamily that
may bind to CD40 CLL cells, rescuing them from apoptosis.67
Conversely, CD40 crosslinking on CLLcells induces up-regulation
of CD80 and CD54 and turns nonimmunogenic CLL cells into
effective T-cell stimulators.68 CLL cells engineered to express
CD154 by adenoviral gene transfer can crosslink CD40 on
bystander CLL cells and induce the same sequence of activation
and immune recognition. When this concept was moved into the
clinic as a novel form of immunotherapy, CLL patients were
infused with their cells transduced in vitro with an adenovirus
encoding CD40L (Ad-CD154).69 Recently, 3 patients treated with
Ad-CD154–transduced CLL cells were shown to make antibodies
to ROR1,55 an oncofetal antigen with surface expression restricted
to CLL B cells. Collectively, these data suggest that CD40 activa-
tion of CLL cells can result in different outcomes that are not
mutually contradictory: activation of prosurvival and proliferation
pathways, if triggered by CD154 T cells in the context of
proliferation centers, or immune recognition and induction of a
speciﬁcimmuneresponse,iftriggeredinthecontextofAd-CD154–
transduced CLLcells.
Microenvironment in follicular lymphoma
A proactive involvement of the microenvironment appears to be
operating in some indolent lymphomas, which tend to retain the
architecture and the cellular microenvironment of normal lymph
nodes. This is particularly true in FL, which faithfully recapitulates
the general architecture of normal follicles, including the presence
of T cells and of a meshwork of FDCs, even when the inﬁltrate
localizes in the BM and in nonlymphoid organs. FL cells, like
normal GC cells, are notoriously difﬁcult to grow in vitro where
they rapidly undergo apoptosis unless stimulated through CD40,70
a main signaling pathway of T- and B-cell interactions. It is also
apparent in marginal zone B-cell lymphomas of MALT-type, where
malignant cells maintain an association with epithelial cells. These
observations indicate that the pioneer colonizing lymphoma cells
that land in the appropriate soil may contribute to render it much
more welcoming and suggest the coevolution of malignant cells
and microenvironment.
Given that the composition of the microenvironment appears to
be a key prognostic factor in FL,15 the relevant question becomes
how such a conducive microenvironment is assembled. It has to be
understood whether the non-B cellular elements in an FL inﬁltrate
outside a lymph node, such as T cells and FDCs, are imported from
outside (eg, from the original lymph node lesion) together with
malignant B cells or whether they are differentiating in situ from
local cells recruited from the different microenvironment elements
of the different organs involved. If the latter hypothesis is correct, it
remains to be established which T-cell subsets are implicated and
through which mechanisms and especially which local stromal
cells are recruited and how the stromal cells differentiate into
FDCs. In this context, a relevant role may be played by MSCs,
which can be part of the normal BM and lymphoid tissue
microenvironment and, as such, might represent the soil where the
neoplastic B cells seed. Alternatively, they may coevolve in the
tumor microenvironment, as it has been shown in some solid
tumors where carcinoma-associated ﬁbroblasts provide growth
signals by secreting CXCL12.71
Lymphoma-associated macrophages (LAMs) conﬁrm the criti-
cal role of myelomonocytic cells in shaping the microenvironment
of some B-cell malignancies. Microarray and immunohistochemis-
try studies15,72,73 suggested a central role of LAMs in the pathogen-
esis and prognosis of FL, indicating the responsiveness of FLs to
microenvironmental signals, especially delivered by these cells.
Because NLCs and LAMs share lineage and high CD68 expres-
sion, they may represent a common master cellular regulator in the
microenvironment of different B-cell tumors. Considering the
general role of macrophages in cancer progression,74 it is not
surprising to ﬁnd them as central players in the FL microenviron-
ment, although one would have also expected FDCs to be
identiﬁed, given the critical role of Ag stimulation in B-cell
malignancies and the role of mesenchymal FDCs6 as prototype
Ag-presenting cells in normal lymphoid follicles. Still, Ag presen-
tation by myelomonocytic cells was long known as an alternative
form of Ag delivery to B cells and has recently gained new
attention.75,76 Rapid in vivo delivery of immune complexes to
macrophages in the lymph node subcapsular sinus and their capture
by follicular B cells were demonstrated using multiphoton intravi-
tal microscopy of lymph nodes.75 It is tempting to speculate that
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or LAMs in the microenvironment of CLLand FL.
Neoplastic follicles contain numerous T cells usually found in
normal GC, including follicular T cells. The role of T cells in
shaping FL microenvironment is unclear, some probably favoring
tumor progression by production of cytokines and/or direct con-
tact.77 Of interest, FOXP3CD4CD25 regulatory T cells are
enriched in FLnodes.78 Tregs play a critical role in the inhibition of
self-reactive immune responses and, as such, have been implicated
in the suppression of tumor-reactive effector T cells in FL, thereby
fostering an immune-privileged microenvironment.79 It is therefore
a relevant observation that FL B cells may be able to induce Foxp3
expression and regulatory function in conventional T cells within
the tumor microenvironment,80,81 thereby allowing FL cells to
evade the immune system detection. However, the biologic and
prognostic role of various non-neoplastic T-cell populations in FL
inﬁltrates is poorly understood, and results from a number of
immunohistochemical studies investigating the number of CD3,
CD4, and CD8 T-cell populations are highly contradic-
tory.72,73,82-86 de Jong et al recently reviewed 9 studies in FL, often
reporting contradictory ﬁndings of FL inﬁltration by accessory
T cells and other stromal cells (macrophages, FDCs), and their
impact on patients’prognosis.85 Lessons from these studies are that
the prognostic role of certain T-cell populations might be highly
dependent on speciﬁc treatment protocols and that the spatial
distribution of T-cell subsets (eg, intrafollicular or extrafollicular)
might be of biologic importance.
Microenvironment in MM
MM has long been the paradigmatic model for investigating the
role of microenvironment in blood cancers. The MM PC precursor
is either an activated B memory cell or a plasmablast31,87 generated
in peripheral lymphoid organs during secondary T cell–dependent
antibody response, programmed to home to the BM and committed
to differentiate in close association with the BM microenviron-
ment.36 Malignant PCs capitalize on the same interactions and
stimuli provided by BM stromal cells that allow for the develop-
ment, survival, and differentiation of normal lympho-hemopoietic
progenitors. MM malignant PCs produce a number of cytokines
that include interleukin-1, TNF-, and monocyte-macrophage
colony stimulating factor,36 which activate the microenvironment.
In turn, the cells of BM microenvironment produce several
cytokines relevant to the growth and survival of MM PCs
epitomized by IL-6 and insulin-like growth factor-I (reviewed by
Hideshima et al36). The physical contact between MM PC and BM
stromal cells increases IL-6 production.88 BM microenvironmental
stromal cells both in mice and in human PC tumors are well
equipped with a large series of adhesion and extracellular matrix
proteins that mediate homotypic and heterotypic interactions and
provide anchorage sites to cells selectively exposed to locally
released growth factors.36
The MM microenvironment has 2 cardinal features. First,
neoangiogenesis is especially prominent. The density of newly
formed microvessels is proportional to the PC labeling index; it
increases with stage and has a strong prognostic value.89 MM cells
produce angiogenic cytokines90; in turn, endothelial cells stimulate
MM cell growth and protect them from drugs.91 The role of
neoangiogenesis, which is also evident in other blood cancers
spanning from CLL92 to myeloﬁbrosis,93 as a therapeutic target in
MM is still unclear. As an example, a number of drugs, such as
thalidomide, lenalidomide, and bortezomib, appear able to counter-
act the nurturing effect of the BM milieu in MM, but their precise
relationship with a direct antiangiogenetic effect has not been
proven. More recently, the possibility has emerged that dasatinib
may target tumor vessels.94
The second important property of the MM microenvironment is
that several of the cytokines that function as growth and survival
factors for monoclonal PC (such as IL-6 and insulin-like growth
factor) are also produced in the context of bone remodeling,
leading to the concept of the vicious cycle between bone resorption
and tumor growth. This notion is at the basis of the microenviron-
ment-targeted treatment centered on blocking osteoclast-mediated
bone resorption, indirectly suppressing the sequela of osteo-
clast activity.
These features still fail to disclose why MM PCs localize
uniquely within the BM where bone resorption and tumor expan-
sion stimulate and excite each other, creating a vicious cycle. The
problems that have to be solved include which properties of BM
microenvironment allow such a unique situation, whether speciﬁc
populations of stromal cells are involved, how osteoimmunology
may provide much needed clues, and how the modiﬁcations of
microenvironment that occur in MM relate to the microenviron-
ment features of monoclonal gammopathy of undetermined
signiﬁcance.
Potential therapeutic targets: the issue of
malignant B-cell niches
Overall, we are only starting to learn which pathways deliver
critical survival and drug-resistance signals in the interactions that
occur between B-cell malignancies and their microenvironments.
The deﬁnition of the architecture of distinct niches for hematopoi-
etic and tissue SC and their relationships with CSC niches, together
with the mechanisms that govern SC migration, homing, and
homeostasis,95 may translate into studies of B-cell malignancies.
Particularly in the early stages, the pathways used by largely
stroma-dependent clones are similar to those used during early
B-cell development in the marrow and Ag-triggered B-cell expan-
sion in follicles.
In this context, a tissue of crucial importance is the BM. Besides
MM, which is by deﬁnition a BM disease, the BM is a common site
of minimal residual disease and the source of relapses in patients
with B-cell tumors, such as CLL. One possible explanation is that,
although conventional treatment eliminates the bulk of clonal
elements, residual malignant cells lurk in protective niches where
they receive signals from accessory cells that promote survival and
drug resistance (Figure 1A). It is reasonable to suggest that these
niches may have similarities with the niches that protect HSCs,
including the presence of stromal cells, T cells, and endothelial
cells. This situation would be optimal to pave the way to relapse.A
similar organization might occur in MM, where it is plausible to
consider that transformed migrating plasmablasts reaching the BM
may organize themselves in niches that would provide the environ-
ment necessary for their differentiation into nonmigratory PCs that
will progressively and successfully occupy the marrow.
Considering that different types of stromal cells are being
implicated in the growth of mature B-cell tumors, a precise
deﬁnition of which cells and through which pathways are operating
in vivo in different malignancies becomes essential. The compel-
ling evidence that interactions with different types of stromal cells,
such as MSCs or NLCs, confer survival- and drug-resistance
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At the same time, it cannot be overlooked that stromal cells are
essential for the tightly regulated tissue homeostasis, providing
niches to normal SCs, such as HSCs. This may result in a
double-edged sword as exempliﬁed when considering CXCR4 as a
molecular therapeutic target. Given the importance of CXCR4 for
malignant B-cell adhesion to MSCs,34 and more generally, its
signiﬁcance for CSC homing to protective niches,96 CXCR4
antagonists (plerixafor/AMD3100, or T140 analogs) could be
useful for mobilizing cancer cells for a more effective exposure to
anticancer drugs.4 However, this approach also mobilizes normal
HSCs (and potentially other SCs) and exposes them to cytotoxic
drugs outside their protective niches, which might result in
increased toxicity. Combinations of CXCR4 antagonists with drugs
that target predominantly the malignant cells, such as monoclonal
antibodies (ie, rituximab, alemtuzumab), could help avoid this
potential hazard.
Targeting the microenvironment: clinical and
preclinical studies
Preliminary data from an ongoing clinical trial in patients with
relapsed leukemia, which combines plerixafor with chemotherapy,
suggest safety and efﬁcacy of the concept to mobilize (using a
CXCR4 antagonist) and then target tumor cells outside their
protective niches.97 Related clinical studies include a CLLtrial that
combines plerixafor with rituximab, and a trial in MM with the
T140 analog BKT140, but preliminary data are not yet available.
Another therapeutic approach that recently entered the clinical
stage is related to the Syk. Syk is a key component of BCR
signaling and can be blocked by R406, a small-molecule Syk
inhibitor. R406 is active in preclinical models in CLL62,98 and
DLBCL30 and displayed impressive activity in CLL patients in a
ﬁrst clinical trial.99 Other therapeutic targets are adhesion mol-
ecules, such as VLA-445 or CD44 as an alternative to CXCR4
antagonists for mobilization of neoplastic cells from their protec-
tive environment. In a ﬁrst clinical trial in myeloma patients, the
anti–VLA-4 antibody natalizumab (Biogen IDEC), approved for
the treatment of multiple sclerosis, is currently being investigated.
Surface molecules or signaling pathways that are involved in
crosstalk between malignant B cells and their microenvironment
(Figure2)alsorepresentattractivetherapeutictargets.Thephospho-
inositide 3-kinases are a key signaling pathway in cancer, including
B-cell malignancies.100 Small molecule phosphoinositide 3-kinase
inhibitors effectively antagonize stromal cell–derived migration,
survival, and drug resistance signals in CLL.100 These drugs are
expected to become available for targeting stroma-derived survival
signals in B-cell malignancies in the near future. Immunomodula-
tory drugs, such as thalidomide and its successor, lenalidomide, are
clinically active in mature B-cell malignancies, including MM and
CLL, and their activity has been related to modulation of the
microenvironment, rather than the malignant B cells. Here, the
precise mechanism(s) remain unknown and are currently the
subject of intensive research. Finally, discovery and targeting of the
causative agents that induce B-cell expansion in the various B-cell
malignancies could be a quintessential goal of our efforts in this
ﬁeld, and the discoveries related to H pylori and its role in
development of MALT lymphoma, as discussed before, are a
paradigm for this concept. Whether or not the concept of CSC
applies to B-cell malignancies remains to be explored, but the
microenvironment dependency and the concept of niches merge
HSC, CSC, and several B-cell malignancies. Likely, a more proper
understanding of these aspects will allow movement toward
additional targeted treatment options.
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